ABSTRACT
Trace amine-associated receptor 1 (TAAR1) is a widely recognized new perspective target for the neuropsychiatric pharmacological treatment. Despite a growing number of studies investigating TAAR1 role in the animal models of different pathologies, information of TAAR1 agonists impact on executive cognitive functions is limited. The goal of the present study was to evaluate the activity of highly selective partial TAAR1 agonist RO5263397 on various executive cognitive functions. The results of the present study demonstrated that the pretreatment with RO5263397 was able to increase attention and decrease cognitive flexibility in rats. The analysis of the RO5263397 action on impulsivity demonstrated that the TAAR1 activation failed to affect premature responding but was able to slightly modify impulsive choice. Problem solving was resistant to the pharmacological intervention.
Subject(s)
Executive Function/drug effects , Executive Function/physiology , Oxazoles/pharmacology , Receptors, G-Protein-Coupled/agonists , Receptors, G-Protein-Coupled/physiology , Animals , Conditioning, Operant/drug effects , Conditioning, Operant/physiology , Dose-Response Relationship, Drug , Male , Rats , Rats, WistarABSTRACT
We provide an overview of the recent achievements in psychiatric genetics research in the Russian Federation and present genotype-phenotype, population, epigenetic, cytogenetic, functional, ENIGMA, and pharmacogenetic studies, with an emphasis on genome-wide association studies. The genetic backgrounds of mental illnesses in the polyethnic and multicultural population of the Russian Federation are still understudied. Furthermore, genetic, genomic, and pharmacogenetic data from the Russian Federation are not adequately represented in the international scientific literature, are currently not available for meta-analyses and have never been compared with data from other populations. Most of these problems cannot be solved by individual centers working in isolation but warrant a truly collaborative effort that brings together all the major psychiatric genetic research centers in the Russian Federation in a national consortium. For this reason, we have established the Russian National Consortium for Psychiatric Genetics (RNCPG) with the aim to strengthen the power and rigor of psychiatric genetics research in the Russian Federation and enhance the international compatibility of this research.The consortium is set up as an open organization that will facilitate collaborations on complex biomedical research projects in human mental health in the Russian Federation and abroad. These projects will include genotyping, sequencing, transcriptome and epigenome analysis, metabolomics, and a wide array of other state-of-the-art analyses. Here, we discuss the challenges we face and the approaches we will take to unlock the huge potential that the Russian Federation holds for the worldwide psychiatric genetics community.
Subject(s)
Intersectoral Collaboration , Mental Disorders/epidemiology , Mental Disorders/genetics , Biomedical Research , Genome-Wide Association Study , Humans , Mental Health/ethnology , Russia/epidemiologyABSTRACT
Thevinols and their 3-O-demethylated relatives, orvinols, are derivatives of the Diels-Alder adduct of natural alkaloid thebaine with methyl vinyl ketone. Taken together, thevinols and orvinols constitute an important family of opioid receptor (OR) ligands playing an important role in both the OR mediated antinociception and OR antagonism. Herein, we disclose for the first time the OR activity of orvinols fluorinated within the pharmocophore associated with C(20) and its surrounding along with a dependence of the activity profile on the substituent at N(17). Starting from thevinone and 18,19-dihydrothevinone, a family of C(21)-fluorinated orvinols bearing methyl, cyclopropylmethyl (CPM), and allyl substituent at N(17) was synthesized. The fluorinated compounds were evaluated for OR activity. The orvinols bearing three fluorine atoms at C(21) were found to retain the properties of OR ligands and their activity profile depends on the substituent at N(17). Pilot in vivo experiments in a model of acute pain (tail-flick test in mice) revealed that 6-O-desmethyl-21,21,21-trifluoro-20-methylorvinol at doses 1.0-10.0Ā mg/kg (s.c.) exhibits analgesic activity at the level of morphine for a duration of 30-180Ā min. Its N(17)-CPM counterpart demonstrated the partial opioid agonist properties. The N(17)-allyl substituted derivative showed no analgesic activity. In vivo evaluation of an analgesic activity indicates that 21,21,21-trifluoro-20-methylorvinols represent a novel family of OR ligands related to buprenorphine, diprenorphine, etc. These compounds are promising for the structure-activity relationship studies among the thevinol/orvinol series as well as for a search for new OR ligands with potentially valuable pharmacological profiles.
Subject(s)
Analgesics, Opioid , Analgesics , Mice , Animals , Analgesics, Opioid/pharmacology , Analgesics/pharmacology , Receptors, Opioid/agonists , Narcotic Antagonists/pharmacology , Structure-Activity Relationship , Ligands , Receptors, Opioid, mu/agonistsABSTRACT
OBJECTIVE: To compare trends in opioid consumption in Israel and St. Petersburg/Russia (morphine, oxycodone, pethidine, fentanyl, methadone, buprenorphine, trimeperidine, and papaveretum) over the period 2000-2008, and to describe the regulatory barriers to their accessibility as an exploratory variable for between-country differences. METHODS: Data were drawn from the databases maintained by the Israel Ministry of Health's Pharmaceutical Administration and the St. Petersburg Central Pharmaceutical Reserve. The data were converted into a defined daily dose (DDD)/1,000 inhabitants/day. Regulation was evaluated according to the WHO guidelines for the assessment of national opioid regulation. RESULTS: The opioid consumption rates in Israel were substantially higher than those in St. Petersburg. The excess in DDD/1,000 inhabitants/day was for fentanyl +0.287 in 2000 and +1.206 in 2008, for morphine +0.245 in 2000 and +0.122 in 2008, and for pethidine/trimeperidine +0.035 in 2000 and +0.007 in 2008. Oxycodone consumption increased in Israel from 0.31 DDD/1,000 inhabitants/day in 2000 to 0.46 DDD/1,000 inhabitants/day in 2008, whereas this analgesic is not available in St. Petersburg. Methadone and buprenorphine consumption rose in Israel, whereas these drugs are not available in Russia. Conversely, omnopon consumption decreased in St. Petersburg from 0.0206 DDD/1,000 inhabitants/day in 2000 to 0.00304 DDD/1,000 inhabitants/day in 2008, whereas the compound is not available in Israel. St. Petersburg differs from Israel with less opioid formulary availability and greater regulatory restrictions. CONCLUSION: The results suggest that strong opioid analgesics consumption rates in St. Petersburg yield those in Israel, and that the between-countries differences in opioid formularies availability and legal and regulatory barriers to opioids accessibility are responsible for the consumption discrepancies.
Subject(s)
Analgesics, Opioid/therapeutic use , Drug Utilization , Drug and Narcotic Control , Health Services Accessibility , Pharmaceutical Services/legislation & jurisprudence , Analgesics, Opioid/supply & distribution , Databases, Factual , Drug Prescriptions , Drug Utilization/trends , Formularies as Topic , Guidelines as Topic , Humans , Israel , Practice Patterns, Physicians' , Russia , Urban Health , World Health OrganizationABSTRACT
RATIONALE: Metabotropic glutamate 1 (mGlu1) receptor antagonists were reported to induce cognitive deficits in several animal models using aversive learning procedures. OBJECTIVE: The present study aimed to further characterize behavioral effects of mGlu1 receptor antagonists using appetitively motivated tasks that evaluate working memory, timing, and impulsivity functions. MATERIALS AND METHODS: Separate groups of adult male Wistar rats were trained to perform four food-reinforced operant tasks: delayed non-matching to position (DNMTP), differential reinforcement of low rates of responding 18 s (DRL 18-s), signal duration discrimination (2-s vs 8-s bisection), and tolerance to delay of reward. Before the tests, rats were pretreated with (3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone methanesulfonate (EMQMCM; 2.5-10 mg/kg, i.p.; JNJ16567083). RESULTS: In DNMTP task, EMQMCM produced delay-dependent increases in performance accuracy so that, at 10 mg/kg dose level, percentage of correct lever choices was enhanced at 8- and 16-s delays. In DRL task, at all three tested doses, response rates were higher, and reinforcement rates were lower than under control conditions. In signal duration discrimination tasks, EMQMCM did not have any specific effects on temporal control. In tolerance to delay of reward, EMQMCM (5 and 10 mg/kg) facilitated choice of the lever associated with large reward at longer delay levels. CONCLUSIONS: Blockade of mGlu1 receptors improves working memory and reduces impulsive choice at the doses that have no effects on time perception but appear to facilitate impulsive action.
Subject(s)
Impulsive Behavior/prevention & control , Memory/drug effects , Quinolines/pharmacology , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Time Perception/drug effects , Analysis of Variance , Animals , Behavior, Animal/drug effects , Conditioning, Operant/drug effects , Discrimination, Psychological , Dose-Response Relationship, Drug , Impulsive Behavior/physiopathology , Inhibition, Psychological , Injections, Intraperitoneal , Male , Quinolines/administration & dosage , Rats , Rats, Wistar , Reinforcement Schedule , RewardABSTRACT
An endogenous natriuretic and vasoconstrictor Na/K-ATPase inhibitor, marinobufagenin (MBG), is implicated in NaCl-induced hypertension and in ethanol addiction. In rats, MBG suppresses voluntary alcohol intake, while immunization against MBG induces alcohol-seeking behavior. Since alcohol withdrawal is associated with elevation of blood pressure (BP) and renal sodium retention, we hypothesized that MBG mediates pressor response to ethanol withdrawal. In male Sprague-Dawley rats, forced ethanol intake (20% v/v, 2.8+/-0.2 g/day for 7 days) did not affect BP and MBG excretion. Ethanol withdrawal was associated with a 21 mm Hg increase in BP, a 10% decrease in hematocrit, and a three-fold increase in renal MBG excretion. In vivo administration of anti-MBG antibody to rats prevented withdrawal-induced BP elevation. Therefore, MBG mediates pressor response to ethanol withdrawal, and may link mechanisms of ethanol dependence and hypertension.
Subject(s)
Blood Pressure/drug effects , Bufanolides/therapeutic use , Central Nervous System Depressants , Ethanol , Substance Withdrawal Syndrome/drug therapy , Substance Withdrawal Syndrome/physiopathology , Vasoconstrictor Agents/therapeutic use , Animals , Bufanolides/urine , Hematocrit , Male , Ouabain/urine , Rats , Rats, Sprague-Dawley , Sodium/urine , Vasoconstrictor Agents/urineABSTRACT
AIM: To assess the effectiveness of a sexual risk reduction intervention in the Russian narcology hospital setting. DESIGN, SETTING AND PARTICIPANTS: This was a randomized controlled trial from October 2004 to December 2005 among patients with alcohol and/or heroin dependence from two narcology hospitals in St Petersburg, Russia. INTERVENTION: Intervention subjects received two personalized sexual behavior counseling sessions plus three telephone booster sessions. Control subjects received usual addiction treatment, which did not include sexual behavior counseling. All received a research assessment and condoms at baseline. MEASUREMENTS: Primary outcomes were percentage of safe sex episodes (number of times condoms were used / by number of sexual episodes) and no unprotected sex (100% condom use or abstinence) during the previous 3 months, assessed at 6 months. FINDINGS: Intervention subjects reported higher median percentage of safe sex episodes (unadjusted median difference 12.7%; P = 0.01; adjusted median difference 23%, P = 0.07); a significant difference was not detected for the outcome no unprotected sex in the past 3 months [unadjusted odds ratio (OR) 1.6, 95% confidence interval (CI) 0.8-3.1; adjusted OR 1.5, 95% CI 0.7-3.3]. CONCLUSIONS: Among Russian substance-dependent individuals, sexual behavior counseling during addiction treatment should be considered as one potential component of efforts to decrease risky sexual behaviors in this HIV at-risk population.
Subject(s)
HIV Infections/prevention & control , Risk Reduction Behavior , Sex Counseling , Substance-Related Disorders/psychology , Unsafe Sex/prevention & control , Adolescent , Adult , Aged , Condoms/statistics & numerical data , Female , Follow-Up Studies , Health Education , Humans , Male , Middle Aged , Russia , Safe Sex , Substance-Related Disorders/therapyABSTRACT
AIMS: We studied whether verapamil, a Ca2+ channel blocker, affects cardiovascular symptoms in alcohol withdrawal. METHODS: Cardiovascular effects of verapamil (5 mg intravenously) were compared in 20 alcohol-dependent subjects during alcohol withdrawal (n = 10) on days 1, 2 and 10 and during early recovery (n = 10; duration 45 +/- 4.1 days). The heart rate was obtained from the electrocardiogram. Systolic and diastolic blood pressures were measured with a sphygmomanometer by Korotkoff. Stroke volume was studied by impedance cardiography. RESULTS: Significant differences in verapamil effects on systolic and diastolic blood pressure and stroke volume and total peripheral resistance were observed in patients with withdrawal when compared with those in early recovery. CONCLUSION: L-type Ca2+ channels may modify vascular tone in alcohol withdrawal.
Subject(s)
Calcium Channel Blockers/therapeutic use , Ethanol/adverse effects , Hemodynamics/drug effects , Substance Withdrawal Syndrome/drug therapy , Verapamil/therapeutic use , Adult , Analysis of Variance , Blood Pressure/drug effects , Calcium Channels, L-Type/metabolism , Electrocardiography , Heart Rate/drug effects , Humans , Male , Sphygmomanometers , Stroke Volume/drug effects , Vascular Resistance/drug effectsABSTRACT
OBJECTIVE: Ethanol blocks N-methyl-d-aspartic acid (NMDA) glutamate receptors. Increased NMDA receptor function may contribute to motivational disturbances that contribute to alcoholism. The authors assessed whether the NMDA receptor antagonist memantine reduces cue-induced alcohol craving and produces ethanol-like subjective effects. METHOD: Thirty-eight alcohol-dependent inpatients participated in three daylong testing sessions in a randomized order under double-blind conditions. On each test day, subjects received 20 mg of memantine, 40 mg of memantine, or placebo, and subjective responses to treatment were assessed. The level of alcohol craving was assessed before and after exposure to an alcohol cue. RESULTS: Memantine did not stimulate alcohol craving before exposure to an alcohol cue, and it attenuated alcohol cue-induced craving in a dose-related fashion. It produced dose-related ethanol-like effects without adverse cognitive or behavioral effects. CONCLUSIONS: These data support further exploration of whether well-tolerated NMDA receptor antagonists might have a role in the treatment of alcoholism.
Subject(s)
Alcoholism/psychology , Behavior, Addictive/psychology , Cues , Ethanol , Excitatory Amino Acid Antagonists/pharmacology , Memantine/pharmacology , Adult , Alcoholism/drug therapy , Behavior, Addictive/drug therapy , Behavior, Addictive/etiology , Cognition/drug effects , Dose-Response Relationship, Drug , Double-Blind Method , Ethanol/pharmacology , Excitatory Amino Acid Antagonists/therapeutic use , Hospitalization , Humans , Male , Memantine/therapeutic use , Verbal Learning/drug effectsABSTRACT
Glutamatergic neurotransmission is believed to be critically involved in the acquisition and maintenance of drug addiction. The present study evaluated the role of metabotropic glutamate (mGlu) 1 receptors in the reinstatement of nicotine-seeking behavior. Rats were trained to nose-poke to receive response-contingent intravenous infusions of nicotine (0.01 mg/kg/infusion, free base). Following the subsequent extinction phase, reinstatement tests were conducted in animals that were exposed either to response-contingent presentations of the nicotine-associated discrete light cues or to non-contingent nicotine priming injection (0.3mg/kg, s.c., salt) just prior to the test session. In a separate experiment, rats were subjected to the nearly identical response-reinstatement procedure but operant responding was established using food pellets instead of nicotine infusions. Pretreatment with the mGlu1 receptor antagonist EMQMCM (JNJ16567083, (3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone methanesulfonate) significantly inhibited cue-induced reinstatement of nicotine-seeking behavior (5 and 10, but not 2.5 mg/kg). EMQMCM (5 mg/kg) also prevented nicotine priming-induced reinstatement of nicotine-seeking behavior. At the highest tested dose only (10 mg/kg), EMQMCM attenuated cue-induced reinstatement of food-seeking behavior. Taken together with the previous reports, the present findings further suggest that blockade of mGlu1 receptors may be beneficial for preventing relapse to tobacco smoking in nicotine-dependent individuals.
Subject(s)
Cues , Extinction, Psychological/drug effects , Nicotine/administration & dosage , Nicotinic Agonists/administration & dosage , Receptors, Metabotropic Glutamate/physiology , Reinforcement, Psychology , Animals , Behavior, Animal , Conditioning, Operant/drug effects , Dose-Response Relationship, Drug , Feeding Behavior/drug effects , Food , Male , Quinolines/pharmacology , Rats , Rats, Wistar , Receptors, Metabotropic Glutamate/antagonists & inhibitors , Self Administration/methodsABSTRACT
This randomized placebo-controlled trial tested the efficacy of oral naltrexone with or without fluoxetine for preventing relapse to heroin addiction and for reducing HIV risk, psychiatric symptoms, and outcome. All patients received drug counseling with parental or significant-other involvement to encourage adherence. Patients totaling 414 were approached, 343 gave informed consent, and 280 were randomized (mean age, 23.6 +/- 0.4 years). At 6 months, two to three times as many naltrexone patients as naltrexone placebo patients remained in treatment and had not relapsed, odds ratio (OR) = 3.5 (1.96-6.12), p < .0001. Overall, adding fluoxetine did not improve outcomes, OR = 1.35 (0.68-2.66), p = .49; however, women receiving naltrexone and fluoxetine showed a trend toward a statistically significant advantage when compared to women receiving naltrexone and fluoxetine placebo, OR = 2.4 (0.88-6.59), p = .08. HIV risk, psychiatric symptoms, and overall adjustment were markedly improved among all patients who remained on treatment and did not relapse, regardless of group assignment. More widespread use of naltrexone could be an important addition to addiction treatment and HIV prevention in Russia.
Subject(s)
Antidepressive Agents, Second-Generation/therapeutic use , Fluoxetine/therapeutic use , Heroin Dependence/rehabilitation , Heroin/adverse effects , Naltrexone/therapeutic use , Narcotic Antagonists/therapeutic use , Substance Abuse, Intravenous/rehabilitation , Substance Withdrawal Syndrome/rehabilitation , Adult , Antidepressive Agents, Second-Generation/adverse effects , Combined Modality Therapy , Double-Blind Method , Drug Therapy, Combination , Female , Fluoxetine/adverse effects , HIV Infections/prevention & control , Humans , Male , Naltrexone/adverse effects , Narcotic Antagonists/adverse effects , Psychotherapy , Russia , Secondary Prevention , Substance Withdrawal Syndrome/diagnosisABSTRACT
Constitutively active 5-HT2 receptors have been suggested to contribute to motoneuronal excitability, muscle spasms and spasticity. Accordingly, 5-HT2C receptor inverse agonists have been demonstrated in pilot experiments to reduce spasticity in animal model of spasticity and patients with spinal cord injuries. Thus, 5-HT2C receptor inverse agonists may represent a novel class of anti-spasticity agents justifying a search for compounds with robust 5-HT2C receptor inverse agonist activity either among the existing medications or via a dedicated drug discovery program. Morphine-induced Straub tail response in mice is regarded as a model of transient spasticity that may be suitable for supporting such drug discovery efforts. Subcutaneous injection of morphine (10-60mg/kg) induced a dose-dependent Straub tail reaction in male Swiss mice with maximum response obtained 15-30min after the morphine administration. When given prior to morphine, 5-HT2B/2C receptor inverse agonists cyproheptadine (1-10mg/kg, i.p.) and SB206553 (0.3-3mg/kg, i.p.) diminished Straub tail reaction dose-dependently without affecting spontaneous locomotor activity. In contrast, 5-HT2B/2C receptor antagonist methysergide (1-5.6mg/kg, i.p.) and 5-HT2C receptor antagonist SB242084 (1-5.6mg/kg, i.p.) as well as 5-HT2A receptor inverse agonist pimavanserin (1-10mg/kg, i.p.) had no appreciable effects on Straub tail response. Taken together, the findings indicate that constitutive activity of 5-HT2B/2C receptor may be involved in the mechanisms of morphine-induced spasticity. Thus, morphine-induced Straub tail response may be evaluated further as a candidate higher throughput test to identify 5-HT2C receptor inverse agonists with anti-spasticity effects in vivo.
Subject(s)
Morphine/pharmacology , Muscle Spasticity/chemically induced , Muscle Spasticity/diet therapy , Serotonin 5-HT2 Receptor Agonists/pharmacology , Serotonin 5-HT2 Receptor Antagonists/pharmacology , Animals , Dose-Response Relationship, Drug , Drug Inverse Agonism , Kinetics , Locomotion/drug effects , Male , Mice , Muscle Spasticity/drug therapy , Muscle Spasticity/physiopathology , Receptor, Serotonin, 5-HT2C/metabolism , Serotonin 5-HT2 Receptor Agonists/therapeutic use , Serotonin 5-HT2 Receptor Antagonists/therapeutic useABSTRACT
Previous studies have indicated that blockade of N-methyl-D-aspartate (NMDA) subtype of glutamate receptors prevents acquisition of instrumental behaviors reinforced by food and drugs such as morphine and cocaine. The present study aimed to extend this evidence by testing whether NMDA receptor channel blocker, memantine, would exert similar effects on acquisition of cocaine and nicotine self-administration in mice. Inasmuch as memantine also acts as nicotinic receptor channel blocker, this study assessed the effects of mecamylamine and MRZ 2/621 that are more selective nicotinic blockers. Adult male Swiss mice were allowed to self-administer cocaine (0.8-2.4 microg/infusion) or nicotine (0.08-0.32 microg/infusion) during the 30-min test. Pretreatment with memantine (0.1-10 mg/kg) prevented acquisition of nicotine but not cocaine self-administration. Pretreatment with mecamylamine (0.3-3 mg/kg) and MRZ 2/621 (0.3-10 mg/kg) produced dose-dependent suppression of both cocaine and nicotine self-administration. Taken together with the previous reports, these results indicate that nicotinic receptor blockers antagonize acute reinforcing effects of cocaine while NMDA receptor blockade may have limited effectiveness.
Subject(s)
Behavior, Addictive/drug therapy , Cocaine/administration & dosage , Nicotine/administration & dosage , Receptors, N-Methyl-D-Aspartate/physiology , Receptors, Nicotinic/physiology , Animals , Dose-Response Relationship, Drug , Excitatory Amino Acid Antagonists/therapeutic use , Infusions, Intravenous , Male , Mice , Nicotinic Antagonists/therapeutic use , Self AdministrationABSTRACT
In contrast to conventional opioid analgesics, antagonists acting at the N-methyl-d-aspartate (NMDA) subtype of glutamate receptors are capable of suppressing pain-related phenomena in chronic pain models while having little or no effect on acute nociception. One of the few clinically used NMDA receptor antagonists, memantine, differs from prototypic antagonists with psychotomimetic activity such as phencyclidine and (+)MK-801, in showing lower receptor affinity, faster unblocking kinetics and stronger voltage-dependency. Recently, a series of novel amino-alkyl-cyclohexanes was reported to interact with NMDA receptors in a manner similar to that of memantine. The present study aimed to evaluate the effects of these compounds as well as (+)MK-801 and memantine in two rat models of chronic pain and the rotarod test. Unlike (+)MK-801 and memantine, most of the tested compounds were inactive against tactile allodynia induced by sciatic nerve ligation. On the other hand, all tested drugs were found to inhibit formalin-induced grooming behavior-a model of chronic pain induction. In agreement with previous reports on the effects of NMDA receptor antagonists in similar assays, the late phase seemed to be inhibited to a greater extent than the early phase. For all tested compounds, inhibition of formalin-induced behaviors occurred at dose levels that were also producing significant motor deficits (rotarod test). These results confirm low efficacy of acute administration of NMDA receptor antagonists in the models of established pain states. Thus, studies on the prevention and management of chronic pain should focus on preemptive or long-term administration of NMDA receptor antagonists.
Subject(s)
Excitatory Amino Acid Antagonists/therapeutic use , Pain/drug therapy , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Animals , Chronic Disease , Dizocilpine Maleate/pharmacology , Electrophysiology , Formaldehyde , Grooming/drug effects , Ligation , Male , Memantine/pharmacology , Oocytes/drug effects , Oocytes/metabolism , Pain Measurement/drug effects , Postural Balance/drug effects , RNA, Complementary/biosynthesis , Rats , Rats, Wistar , Receptors, N-Methyl-D-Aspartate/biosynthesis , Receptors, N-Methyl-D-Aspartate/genetics , Sciatic Nerve/physiology , Sciatic Neuropathy/drug therapy , Sciatic Neuropathy/psychology , XenopusABSTRACT
The deprivation effect (DE)--an increase in the level of free-choice consumption of alcohol after a period of forced abstinence--may reflect relapselike drinking and be relevant for modeling alcohol abuse. However, the behavioral mechanisms of the DE are unclear. In these experiments, rats had unlimited free-choice access to water and saccharin-containing solutions and underwent repeated episodes of saccharin deprivation. It was found that DE magnitude correlates positively with the deprivation phase duration, expression of the DE is highly context dependent, and the DE can be prevented by extinguishing response to the saccharin-associated stimuli. Thus, DE procedures may be useful for studying the effects of continued exposure to stimuli associated with various primary reinforcers such as drugs of abuse.
Subject(s)
Behavior, Animal/drug effects , Food Deprivation , Saccharin/pharmacology , Analysis of Variance , Animals , Association , Behavior, Animal/physiology , Choice Behavior/drug effects , Dose-Response Relationship, Drug , Environment , Male , Rats , Rats, Wistar , Sweetening Agents/pharmacology , Time FactorsABSTRACT
Volatile organic solvents, fuels and anesthetics are subject to abuse. The aim of the present study was to evaluate i.v. self-administration of several of these chemicals in drug- and experiment-naive mice using a commercially available vehicle, intralipid. Two strains of mice (DBA/2 and Swiss) were allowed to self-administer toluene (0.0017-0.17 micromol/infusion), 1,1,1-trichloroethane (0.006-0.19 micromol/infusion), ethanol (0.32-1.6 micromol/infusion), cyclohexane (0.0017-0.052 micromol/infusion), propofol (0.01-0.53 micromol/infusion) and flurothyl (0.00042-0.072 micromol/infusion) or their vehicles during 30-min tests. During the test, each nose-poke of the master mouse resulted in a 1.88-microl i.v. infusion to the master mouse and a yoked control mouse. When the delivery line was loaded with a reinforcing drug solution, the number of nose-pokes of the master mice significantly exceeded that for yoked control mice. In the present experiments, significant differences in rates of nose-poking were observed between mice receiving response-contingent and response-noncontingent deliveries of ethanol and toluene in both strains of mice and of 1,1,1-trichloroethane in Swiss mice. These data suggest that the reinforcing effects of abused inhalants can be studied using i.v. self-administration procedures.
Subject(s)
Anesthetics/administration & dosage , Illicit Drugs/pharmacology , Reinforcement Schedule , Solvents/administration & dosage , Animals , Dose-Response Relationship, Drug , Injections, Intravenous , Male , Mice , Mice, Inbred DBA , Self AdministrationABSTRACT
This review addresses possible involvement of endogenous digitalis-like sodium pump ligands (SPL) in the mood control and ethanol addiction. Endogenous SPL include cardenolide and bufadienolide classes. Multiple SPL and multiple isoforms of the Na/K-ATPase, one of the key membrane enzymes, comprise a complex regulatory system. In the nervous system, pattern of expression of Na/K-ATPase is based on multiple alpha/beta isoform combinations. Clinical studies demonstrate changes in the activity of Na/K-ATPase in patients with bipolar and unipolar mood disorders. The effects of ethanol on the Na/K-ATPase are concentration-dependent and are associated with both inhibition and activation of enzyme activity. Reinforcing effect of ethanol as well as its voluntary consumption may be affected by digitalis glycosides and endogenous SPL.
Subject(s)
Affect/physiology , Alcoholism/enzymology , Digoxin , Enzyme Inhibitors/metabolism , Saponins/metabolism , Sodium-Potassium-Exchanging ATPase/metabolism , Affect/drug effects , Animals , Cardenolides , Enzyme Inhibitors/pharmacology , Humans , Ligands , Saponins/pharmacology , Sodium-Potassium-Exchanging ATPase/antagonists & inhibitorsABSTRACT
In the present study the hypothesis was tested that sodium pump ligands (SPL) can modulate alcohol-seeking behavior and that this effect is related to changes in Na/K-ATPase activity in the central nervous system. Mice were tested for initiation of ethanol intravenous self-administration (IVSA) following i.p. pretreatment with vehicle or the endogenous SPL, marinobufagenin (MBG). Drug- and experimentally-naive mice acquired IVSA of 2% ethanol during a single 30-min session. MBG was found to dose-dependently attenuate (1.25-2.5 microg/kg) initiation of ethanol IVSA producing a decrease in the ratio and in the difference between operant responses of response-dependent and yoked animals as well as a decrease in percentage of mice demonstrating ethanol-seeking behavior. Attenuation of the reinforcing effect of ethanol resulting from MBG was associated with brain levels of this steroid capable of concurrently inhibiting Na/K-ATPase in the brain cortex. We hypothesize that endogenous digitalis-like factors could modulate the reinforcing effect of ethanol.
Subject(s)
Alcohol Drinking/drug therapy , Behavior, Addictive/drug therapy , Bufanolides/therapeutic use , Cerebral Cortex/enzymology , Digoxin , Enzyme Inhibitors/therapeutic use , Sodium-Potassium-Exchanging ATPase/antagonists & inhibitors , Alcohol Drinking/metabolism , Animals , Behavior, Addictive/enzymology , Bufanolides/pharmacology , Cardenolides , Cerebral Cortex/drug effects , Dose-Response Relationship, Drug , Enzyme Inhibitors/pharmacology , Male , Mice , Mice, Inbred DBA , Saponins/blood , Saponins/metabolism , Saponins/pharmacology , Sodium-Potassium-Exchanging ATPase/metabolismABSTRACT
The social group experience of mice with opposite aggressive and nonaggressive behavioral strategies was examined to modulate reinforcing effects of morphine and cocaine. Highly aggressive and nonaggressive male mice cohoused for long period in three-member groups were tested to self-administrate the drugs and to develop conditioned place preferring by them. Mouse triads formed by principle of descending aggression were used as a model of linear hierarchical group. The level of mouse aggression was identified previously within the stock group and during encounter with unknown intruder that continued to be stable over the time of experiment. Highly aggressive mice self-administered morphine and cocaine at higher unit concentrations (1.5 and 1.5 mg/ml) as compare with nonaggressive animals (0.5 and 0.25, 0.5, 1.0 mg/ml). Both morphine (2.5, 5.0, 10.0, and 20.0 mg/kg) and cocaine (2.5, 5.0, and 10.0 mg/kg) induced conditioned place preference in nonaggressive mice at all doses. In contrast, morphine had no effect in highly aggressive mice, while cocaine induced place conditioning at the highest doses (10 mg/kg) only. Our results illustrate that social experience in a stable group alter mouse sensitivity to the rewarding properties of drugs of abuse and social state should be taken into account in the experiments when social interactions are present.
Subject(s)
Aggression/drug effects , Analgesics, Opioid/pharmacology , Behavior, Animal/drug effects , Cocaine/pharmacology , Morphine/pharmacology , Animals , Dose-Response Relationship, Drug , Injections, Intravenous , Male , Mice , Pain Measurement/drug effects , Phenotype , Reinforcement, Psychology , Self Administration , Social Behavior , Social DominanceABSTRACT
INTRODUCTION: An epidemic of syphilis and other sexually transmitted infections (STI) in the Russian Federation is believed to be related to the rise in injection drug use. A study was carried out in collaboration with a non-governmental organization, Foundation 'Vozvrastcheniye'. METHODS: Nine hundred and ten injection drug users participating in the programme were tested for syphilis, HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV); 65 participants who had laboratory markers for syphilis and 45 syphilis-negative serosurvey subjects agreed to participate in a questionnaire study. RESULTS: Syphilis, HIV, HBV and HCV were diagnosed in 12%, 0%, 48% and 79% of drug users, respectively. Prevalence of syphilis seromarkers was nine times higher in females than in males, and strongly associated with sex work. CONCLUSIONS: The results of the study indicate that resources to treat and prevent further infections including HIV should be prioritized toward risk reduction in drug injectors and sex workers in St Petersburg.